LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Inicio・Lista de Acciones・Innoviva Inc

Innoviva Inc

Cerrado

SectorSanidad

22.12 1.98

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

21.6

Máximo

22.4

Métricas clave
By Trading Economics
Ingresos	-55M 187M
Ventas	-20M 98M
P/B Media del Sector	3.436 49.888
BPA	0.47
Margen de beneficios	190.415
Empleados	159
EBITDA	-160M 48M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+61.59% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-115M 1.6B
Apertura anterior	20.14
Cierre anterior	22.12

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

88 / 344 Clasificación en Healthcare

Innoviva Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 jun 2026, 23:22 UTC

Ganancias

Principales Movimientos del Mercado

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 jun 2026, 23:09 UTC

Acciones populares

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 jun 2026, 20:51 UTC

Ganancias

Costco Reports 15% Sales Growth in May

3 jun 2026, 20:43 UTC

Ganancias

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 jun 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 jun 2026, 23:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 jun 2026, 23:35 UTC

Charlas de Mercado

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 jun 2026, 23:15 UTC

Charlas de Mercado

Ganancias

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 jun 2026, 22:08 UTC

Acciones populares

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 jun 2026, 21:54 UTC

Charlas de Mercado

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 jun 2026, 21:18 UTC

Ganancias

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 jun 2026, 21:15 UTC

Ganancias

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 jun 2026, 21:13 UTC

Ganancias

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 jun 2026, 21:13 UTC

Ganancias

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 jun 2026, 21:12 UTC

Ganancias

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 jun 2026, 21:09 UTC

Ganancias

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 jun 2026, 21:03 UTC

Ganancias

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 jun 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

3 jun 2026, 20:43 UTC

Ganancias

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 jun 2026, 20:39 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 jun 2026, 20:37 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 jun 2026, 20:35 UTC

Ganancias

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 jun 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 jun 2026, 20:17 UTC

Ganancias

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 jun 2026, 20:17 UTC

Ganancias

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 jun 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 jun 2026, 20:15 UTC

Ganancias

Broadcom 2Q Adj EPS $2.44 >AVGO

3 jun 2026, 20:15 UTC

Ganancias

Broadcom 2Q EPS $1.91 >AVGO

3 jun 2026, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

3 jun 2026, 20:15 UTC

Ganancias

Broadcom 2Q Rev $22.19B >AVGO

Comparación entre iguales

Cambio de precio

Innoviva Inc previsión

Precio Objetivo

By TipRanks

61.59% repunte

Estimación a 12 Meses

Media 34.5 USD 61.59%

Máximo 46 USD

Mínimo 18 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Innoviva Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

88 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.